VSTM - Verastem Inc logo

Verastem Inc

VSTM

Verastem Inc develops and commercializes biopharmaceuticals targeting RAS/MAPK pathway-driven cancers. Its key products include Avutometinib and Defactinib, designed to inhibit critical signaling pathways in cancer cells and improve treatment outcomes.

โš•๏ธ Healthcare NASDAQ Listed 2012 $ USD
$1,000 invested 10 years ago โ†’$548today

Score Overview

1 Year
Score
Net Growth3.23%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth183.13%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.5
Net Growth-184.69%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth42x
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-456.25%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev Trend60%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-4x
Net Trend21%
Net Income Consistency
Rev Growthโ€”
Rev Trend43%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Verastem Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. VSTM does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 9.21โ€”
1 Year2025-10-21
$ 7.9915.27%
5 Years2021-10-21
$ 31.32-70.59%
10 Years2016-10-21
$ 16.80-45.18%
All Time2012-01-27
$ 133.08-93.08%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 87M-$ 202M$ 136M
2025$ 30M-$ 209M$ 204M
2024$ 10M-$ 130M$ 88M
2023$ 0.00-$ 87M$ 137M
2022$ 2M-$ 73M$ 87M
2021$ 2M-$ 71M$ 100M
2020$ 88M-$ 67M$ 141M
2019$ 17M-$ 149M$ 75M
2018$ 26M-$ 72M$ 249M
2017$ 0.00-$ 67M$ 86M
2016$ 0.00-$ 36M$ 80M
2015$ 0.00-$ 57M$ 110M
2014$ 0.00-$ 53M$ 92M
2013$ 0.00-$ 41M$ 101M
IPO2012$ 0.00-$ 31M$ 56M
VSTM - Verastem Inc logo

Verastem Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 88M to $ 30M and net income went from -$ 67M to -$ 209M. Revenue increased in 4 of those 5 years; net income in 1.

Verastem Inc currently holds a 5-year HDB Score of 3.5 out of 10. How the HDB Score is calculated.

Membership

Explore VSTM with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies